Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease

References

• Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14:264–74.
   PubMed Web of Science ®Google Scholar
• Kawasumi H, Gono T, Kawaguchi Y, Yamanaka H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;9:9–17.
   PubMed Web of Science ®Google Scholar
• Samuels MP, Warner JO. Pulmonary alveolar lipoproteinosis complicating juvenile dermatomyositis. Thorax. 1988;43:939–40.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215–35.
   PubMed Web of Science ®Google Scholar
• Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;161:1294–9.
   PubMed Web of Science ®Google Scholar
• Shiomi A, Usui T. Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm. 2015;2015:568543.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Katoh S, Kadota J, Matsubara Y, Fukushima K, Mukae H, et al. Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease. Eur Respir J. 2000;16:959–64.
   PubMed Web of Science ®Google Scholar
• Xing Z, Braciak T, Ohkawara Y, Sallenave JM, Foley R, Sime PJ, et al. Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. J Leukoc Biol. 1996;59:481–8.
   PubMed Web of Science ®Google Scholar
• Xing Z, Ohkawara Y, Jordana M, Graham F, Gauldie J. Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. J Clin Invest. 1996;97:1102–10.
   PubMed Web of Science ®Google Scholar
• Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, Mimori T. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J Immunol. 2014;193:849–59.
   PubMed Web of Science ®Google Scholar
• Ishii H, Tazawa R, Kaneko C, Saraya T, Inoue Y, Hamano E, et al. Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan. Eur Respir J. 2011;37:465–8.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752–62.
   PubMed Web of Science ®Google Scholar
• Nagasawa J, Kurasawa K, Maezawa R, Owada T, Hanaoka R, Fukuda T. Systemic lupus erythematosus complicating autoimmune pulmonary alveolar proteinosis that was worsened by immunosuppressive therapy. Lupus. 2013;22:1060–3.
   PubMed Web of Science ®Google Scholar
• Kinehara Y, Kida H, Inoue Y, Hirose M, Nakabayashi A, Takeuchi Y, et al. Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosis. BMC Pulm Med. 2014;14:172.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65:745–52.
   PubMed Web of Science ®Google Scholar
• Wardwell NR, Jr., Miller R, Ware LB. Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. Respirology. 2006;11:663–5.
   PubMed Web of Science ®Google Scholar
• Kadikoy H, Paolini M, Achkar K, Suki W, Gaber AO, Anwar N, et al. Pulmonary alveolar proteinosis in a kidney transplant: a rare complication of sirolimus. Nephrol Dial Transplant. 2010;25:2795–8.
   PubMed Web of Science ®Google Scholar
• Shah SK, Phan NB, Goyal G, Sharma G. Pulmonary alveolar proteinosis in a 67-year-old woman with Wegener's granulomatosis. J Gen Intern Med. 2010;25:1105–8.
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Kojima K, Tomimasu R, Fukushima N, Hayashi S, Sueoka E, et al. ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia. Int J Hematol. 2014;100:611–14.
   PubMed Web of Science ®Google Scholar
• Meager A, Wadhwa M, Bird C, Dilger P, Thorpe R, Newsom-Davis J, et al. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology. 1999;97:526–32.
   PubMed Web of Science ®Google Scholar
• Akasaka K, Tanaka T, Kitamura N, Ohkouchi S, Tazawa R, Takada T, et al. Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. BMC Pulm Med. 2015;15:88.
   PubMed Web of Science ®Google Scholar
• Ishii H, Seymour JF, Tazawa R, Inoue Y, Uchida N, Nishida A, et al. Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulm Med. 2014;14:37.
   PubMed Web of Science ®Google Scholar
• Tazawa R, Inoue Y, Arai T, Takada T, Kasahara Y, Hojo M, et al. Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest. 2014;145:729–37.
   PubMed Web of Science ®Google Scholar
• Leth S, Bendstrup E, Vestergaard H, Hilberg O. Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013. Respirology. 2013;18:82–91.
   Google Scholar
• Garber B, Albores J, Wang T, Neville TH. A plasmapheresis protocol for refractory pulmonary alveolar proteinosis. Lung. 2015;193:209–11.
   PubMed Web of Science ®Google Scholar